Novo Nordisk | NVO - Operating Expenses


Novo Nordisk reported DKK6.5B in Operating Expenses for its fiscal quarter ending in June of 2025.





Operating Expenses Change Date
ANI Pharmaceuticals USD 562.3M 344.37M Mar/2026
Aurora Cannabis CAD 129.98M 16.05M Dec/2025
Bausch Health Companies USD 2.04B 42M Mar/2026
Bristol-Myers Squibb USD 20.07B 11.77B Mar/2026
Canopy Growth CAD 87.2M 6.22M Dec/2025
Corcept Therapeutics USD 214.5M 16.87M Mar/2026
Drreddys Laboratories INR 72.94B 4.33B Dec/2025
Eli Lilly USD 10.02B 285M Mar/2026
GlaxoSmithKline GBP 5.34B 1.85B Mar/2026
Merck USD 18.17B 8.01B Mar/2026
Nektar Therapeutics USD 40.9M 44.19M Dec/2025
Novartis USD 9.29B 507M Mar/2026
Novo Nordisk DKK 37.21B 9.56B Mar/2026
Novo Nordisk DKK 6.5B 32.8B Jun/2025
Pacira USD 172.75M 20.93M Mar/2026
Perrigo USD 935.6M 89.6M Mar/2026
Phibro Animal Health USD 361.83M 29.47M Mar/2026
Prestige Brands USD 206.12M 5.17M Mar/2026
Sanofi EUR 9.31B 1.2B Mar/2026
Supernus Pharmaceuticals USD 1.08B 879.06M Mar/2026
Zoetis USD 3.23B 1.68B Mar/2026